| mRNA vaccines—a new era in vaccinology N Pardi, MJ Hogan, FW Porter, D Weissman Nature reviews Drug discovery 17 (4), 261-279, 2018 | 4362 | 2018 |
| Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination N Pardi, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, ... Nature 543 (7644), 248-251, 2017 | 974 | 2017 |
| Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses N Pardi, MJ Hogan, MS Naradikian, K Parkhouse, DW Cain, L Jones, ... Journal of Experimental Medicine 215 (6), 1571-1588, 2018 | 524 | 2018 |
| Recent advances in mRNA vaccine technology N Pardi, MJ Hogan, D Weissman Current opinion in immunology 65, 14-20, 2020 | 489 | 2020 |
| SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation K Lederer, D Castaño, DG Atria, TH Oguin, S Wang, TB Manzoni, ... Immunity 53 (6), 1281-1295. e5, 2020 | 392 | 2020 |
| A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice D Laczkó, MJ Hogan, SA Toulmin, P Hicks, K Lederer, BT Gaudette, ... Immunity 53 (4), 724-732. e7, 2020 | 369 | 2020 |
| mRNA vaccines in the COVID-19 pandemic and beyond MJ Hogan, N Pardi Annual review of medicine 73 (1), 17-39, 2022 | 229 | 2022 |
| Innate immune mechanisms of mRNA vaccines R Verbeke, MJ Hogan, K Loré, N Pardi Immunity 55 (11), 1993-2005, 2022 | 228 | 2022 |
| Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates KO Saunders, N Pardi, R Parks, S Santra, Z Mu, L Sutherland, R Scearce, ... npj Vaccines 6 (1), 50, 2021 | 75 | 2021 |
| Mutations in HIV-1 envelope that enhance entry with the macaque CD4 receptor alter antibody recognition by disrupting quaternary interactions within the trimer DF Boyd, D Peterson, BS Haggarty, APO Jordan, MJ Hogan, L Goo, ... Journal of virology 89 (2), 894-907, 2015 | 55 | 2015 |
| Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization MJ Hogan, A Conde-Motter, APO Jordan, L Yang, B Cleveland, W Guo, ... Virology 514, 106-117, 2018 | 27 | 2018 |
| Induction of Tier 1 HIV neutralizing antibodies by envelope trimers incorporated into a replication competent vesicular stomatitis virus vector CA Bresk, T Hofer, S Wilmschen, M Krismer, A Beierfuß, G Effantin, ... Viruses 11 (2), 159, 2019 | 20 | 2019 |
| Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response MJ Hogan, N Maheshwari, BE Begg, A Nicastri, EJ Hedgepeth, ... Nature Immunology 24 (11), 1933-1946, 2023 | 12 | 2023 |
| MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer H Liao, C Barra, Z Zhou, X Peng, I Woodhouse, A Tailor, R Parker, ... Nature Communications 15 (1), 661, 2024 | 8 | 2024 |
| Nucleoside-modified RNA for inducing an immune response against zika virus D Weissman, N Pardi, M Hogan US Patent 11,241,490, 2022 | 1 | 2022 |
| Author Correction: Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates KO Saunders, N Pardi, R Parks, S Santra, Z Mu, L Sutherland, R Scearce, ... npj Vaccines 6, 2021 | 1 | 2021 |
| Immunization with live influenza virus induces greater polyfunctional CD4+ T cell response compared to inactivated virus M Hogan, W Song, L Eisenlohr Molecular Immunology 150, 29, 2022 | | 2022 |
| Improving Vaccine Design for Viral Diseases Using Modified Antigens and Vectors MJ Hogan University of Pennsylvania, 2017 | | 2017 |
Norbert PardiUniversity of PennsylvaniaBestätigte E-Mail-Adresse bei mail.med.upenn.edu